Big Take Generic Versions of Weight Loss Drugs Will Upend the Market
31 snips
Feb 5, 2026 Amber Tong, Bloomberg reporter on Asian pharma, gives on-the-ground views of China and India markets. Naomi Kresge, Bloomberg health reporter, analyzes patent moves and industry trends. They discuss semaglutide’s rise, how compounded copies differ from regulated generics, Canada as a test market, and why India and China will reshape global supply and pricing.
AI Snips
Chapters
Transcript
Episode notes
Semaglutide Fueled Rapid Market Growth
- Semaglutide sales exploded after FDA approval, driving a massive market for diabetes and weight-loss drugs.
- Novo Nordisk dominated the market but now faces a sharp sales outlook as patents expire and competition rises.
Patent Cliff Opens Global Markets
- Patents for semaglutide are starting to lapse in major markets like Canada, China, and India.
- That opens the door for generic makers and could trigger a seismic change in global availability.
Regulation Shapes Generic Rollout Speed
- Regulatory approvals, not patent expiry alone, determine how fast generics reach patients.
- Canada serves as an early test case, but approvals can still take months or years in each market.